This energy stock could be a reasonably safe pick in 2026.In a market obsessed with artificial intelligence stocks and high-flying meme names, midstream oil and gas player Enterprise Products Partners (EPD 0.48%) has not received the attention it deserves.This oil and gas pipeline operator, which is structured as a master limited partnership (MLP), offers a distribution (dividend) yield of 6.2% and has increased its distributions for 28 consecutive years.Enterprise Products Partners also boasts strong finan ...

Core Viewpoint - Boston Scientific Corporation is under investigation for potential violations of federal securities laws following its fourth-quarter 2025 earnings report, which revealed a significant shortfall in its electrophysiology segment sales compared to market expectations [1][5]. Financial Performance - Boston Scientific reported fourth-quarter 2025 earnings, exceeding analyst expectations for earnings per share and total revenue, but its electrophysiology segment sales were $890 million, approximately $43 million below the consensus estimate of $933 million [2]. - The company had previously guided for organic growth of 11% to 13% for the fourth quarter, but management indicated confidence in only about 15% growth going forward, which is significantly lower than the market's expectation of approximately 25% [4][5]. Market Dynamics - The electrophysiology market is one of the fastest-growing areas in cardiovascular medicine, with pulsed field ablation technology emerging as a potential alternative to traditional thermal ablation procedures [3]. - Boston Scientific entered this market through its acquisition of Farapulse in 2021 and has made substantial investments in expanding manufacturing capacity and physician training programs [3]. Growth Projections - The company projected that global penetration of pulsed field ablation technology would reach 50% by the end of 2025 and grow to approximately 80% by 2028 [3]. - The company emphasized strong growth rates in its electrophysiology segment, reporting 94% growth in Q2 2025 and 63% growth in Q3 2025 [4]. Stock Market Reaction - Following the earnings release, Boston Scientific's shares fell by 17.5%, reaching a 52-week low of $75.50, indicating a negative market reaction to the earnings report and growth outlook [5].

At 11:54 am, the SBI stock was trading at 1137.80, up 71 points or 6.7% on the BSE. Income from core lending activity stayed firm. Net Interest Income rose 9% year-on-year to Rs 45,190 crore. Operating profit, calculated before provisions and contingencies, advanced 40% from the same period last year to Rs 32,862 crore, reflecting improved leverage in the business. Brokerages tracking the lender largely maintained positive recommendations, with many highlighting growth in loans, steady profitability and com ...

Core Viewpoint - State Bank of India (SBI) reported a strong third-quarter net profit of ₹21,030 crore, exceeding estimates by 18%, driven by higher fee income and lower provisions, leading to bullish price targets from various brokerages, with some reaching as high as ₹1,300 [1][10]. Financial Performance - Net interest income increased by 9% year-on-year and 5% quarter-on-quarter to ₹45,190 crore, aligning with estimates [6][11]. - The net interest margin improved to 2.99%, with domestic margins rising to 3.12%, and the bank anticipates margins above 3% in fiscal 2026 and beyond [6][11]. - The loan book grew by 15.6% year-on-year and 6.1% quarter-on-quarter, while deposits increased by 9% and 2%, respectively [9][11]. Brokerage Ratings and Price Targets - Jefferies maintained a Buy rating with a price target of ₹1,300, up from ₹1,190, citing a 1.5x valuation on adjusted book value for March 2028 and projecting a 12% compound annual growth in core profit over fiscal 2026-28 [2][10]. - Motilal Oswal matched the ₹1,300 target, valuing the bank at 1.4 times fiscal 2028 adjusted book value plus ₹354 for subsidiaries, while raising earnings estimates by 3% and 4.3% for fiscal 2027-28 [3][10]. - Nomura raised its target price to ₹1,235 from ₹1,100, reflecting an improved return on equity outlook [7][11]. - JP Morgan maintained an Overweight rating and increased its price target to ₹1,250, revising fiscal 2026 earnings estimates by 7% [7][8][11]. - BofA Securities adopted a more cautious stance, maintaining a Neutral rating with a new price objective of ₹1,100, citing balanced risk-reward at current valuations [9][11]. Asset Quality and Capital Adequacy - The bank's asset quality showed improvement, with slippages moderating and credit costs remaining low at 29 basis points [3][11]. - The CET-1 capital adequacy ratio stood at 11%, indicating a healthy capital position [2][10].

In this article, we will look at the 14 Best NYSE Penny Stocks to Buy Now.Small-cap and penny stocks are having a moment at the start of the new year. The Russell 2000 index is already up by more than 5%, a significant gain given that the S&P 500 is up by just 1.7% over the same period. The rally comes amid growing expectations that the companies are poised to deliver market-beating results while trading at highly discounted valuations.Growing expectations of further monetary policy easing from the Federal ...

Core Viewpoint - REGENXBIO Inc. is under investigation for potential violations of federal securities laws following the FDA's clinical holds on its RGX-111 and RGX-121 programs, which resulted in a significant decline in the company's share price by 30-35% after the announcement [1]. Regulatory Compliance - SEC disclosure rules mandate that public companies must provide material information for informed investment decisions, with Item 8.01 of Form 8-K allowing disclosure of material events not covered by other items [2]. - Rule 10b-5 under the Securities Exchange Act of 1934 prohibits material misstatements and omissions in securities transactions, covering both false statements and omissions of necessary facts [2]. Company Communication - During the Q3 2025 earnings call, CEO Curran Simpson highlighted positive regulatory interactions, noting that the FDA completed inspections with no observations, which may have created an asymmetric view of the company's regulatory status by not disclosing safety concerns being evaluated [3]. - The Q3 2025 earnings call transcript notably lacked any discussion regarding the RGX-111 program for MPS I, despite it being a significant pipeline asset that later faced the same FDA clinical hold, raising concerns about the completeness of information provided to shareholders [4].

Core Viewpoint - PayPal Holdings, Inc. is under investigation for potential violations of federal securities laws following disappointing earnings results and significant stock price decline [1][5]. Group 1: Analyst Expectations and Company Communications - On January 28, 2026, Rothschild & Co Redburn downgraded PayPal's price target from $70 to $50, followed by Morgan Stanley on January 29, 2026, citing slower checkout growth [2]. - Analysts expected mid-single-digit revenue growth and higher earnings per share just before the earnings announcement on February 2, 2026 [2]. Group 2: Earnings Results and Guidance - Actual revenue reported on February 3, 2026, was $8.68 billion, missing the estimate of $8.80 billion by $120 million, a shortfall of approximately 1.4% [3]. - Adjusted earnings per share of $1.23 fell short of the consensus range of $1.30 to $1.33, representing a miss of 5.4% to 7.5% [3]. - The company's forward guidance indicated a decline in transaction margin dollars for 2026, with adjusted earnings per share projected to show a low single-digit decline to a slight positive gain, significantly below market expectations [3]. Group 3: Management Communication and Investigation - During the third quarter 2025 earnings call on October 28, 2025, management did not signal any forthcoming dramatic revisions to the company's outlook [4]. - The investigation will focus on the information available to management prior to the earnings announcement and when the need for lowered guidance became apparent internally [4]. Group 4: Market Reaction - Following the earnings miss on February 3, 2026, PayPal shares dropped 19-20%, reaching approximately $42 and establishing a new 52-week low [5]. - There was a reported sharp increase in short interest as traders anticipated further declines in the stock price [5].

Core Viewpoint - Corcept Therapeutics Incorporated is under investigation for potential violations of federal securities laws following the FDA's denial of approval for its new drug application for relacorilant, which is intended to treat hypertension secondary to hypercortisolism [1][2]. Company Summary - On December 31, 2025, Corcept announced it received a Complete Response Letter (CRL) from the FDA, which denied the approval of relacorilant, citing the need for additional evidence of effectiveness despite acknowledging previous trial results [2]. - The stock price of Corcept fell by $31.42 (44.76%) to open at $38.78 per share on the same day, marking a new 52-week low and reaching levels not seen since September 2024 [3].

BATIDERO, Argentina, Feb 9 (Reuters) - High in the Andes Mountains, more than 4,200 meters above sea level on the Argentina–Chile border, mining company Vicuña Corp. aims to double its investment this year in ​one of the world’s biggest copper bets, a company executive said. Vicuña Corp., formed by Australia’s BHP and ‌Canada’s Lundin Mining, could invest about $800 million this year in the Filo del Sol and Josemaría mines, according to communications director Caterina Dzugala. The two ‌projects could tur ...

State Bank of India (SBI) remains the 'top stock' for analysts as the state-owned lender's December quarter (Q3FY26) results beat Street estimates by a decent margin. Besides, SBI’s core earnings staying stronger than private banks for a third consecutive quarter has also prompted some brokerages to lift their earning estimates and share price target on the stock.   Those at Emkay Global Financial Services, for instance, have raised their FY26-28 earnings estimates by 2-4 per cent, while raising the targe ...